BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Multiple sclerosis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for multiple sclerosis: 175 (89 sponsors; 27 newly posted in the last 180 days, 6 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 22, rank 22 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 28, Phase 2 43, Phase 3 45, Phase 4 9, N/A 50.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Hoffmann-La Roche | 23 | P3 11, NA 2, P4 1, P2 6, P1 3 | 4 | 0 |
| Novartis Pharmaceuticals NVS | 29 | P3 9, NA 13, P2 3, P4 4 | 3 | 6 |
| Sanofi SNY | 7 | P2 1, P3 5, NA 1 | 2 | 1 |
| TG Therapeutics, Inc. TGTX | 9 | P3 4, P2 1, NA 3, P1 1 | 0 | 2 |
| Biogen BIIB | 5 | P3 2, NA 3 | 0 | 0 |
| Immunic AG IMUX | 3 | P2 1, P3 2 | 0 | 0 |
| Zenas BioPharma (USA), LLC ZBIO | 3 | P2 1, P3 2 | 0 | 0 |
| Bristol-Myers Squibb BMY | 7 | P3 1, NA 5, P4 1 | 1 | 1 |
| Amgen AMGN | 1 | P3 1 | 0 | 1 |
| Biocad | 1 | P3 1 | 0 | 0 |
| Celltrion | 1 | P3 1 | 0 | 1 |
| Coya Therapeutics COYA | 1 | P3 1 | 0 | 1 |
| MediciNova MNOV | 1 | P3 1 | 0 | 1 |
| Oculis OCS new entrant | 1 | P3 1 | 1 | 0 |
| Oils4Cure | 1 | P3 1 | 0 | 0 |
| RVL Pharmaceuticals, Inc. | 1 | P3 1 | 0 | 0 |
| Sandoz | 1 | P3 1 | 0 | 0 |
| AbelZeta Inc. new entrant | 2 | P2 1, P1 1 | 2 | 0 |
| AstraZeneca AZN | 2 | P2 1, P1 1 | 0 | 0 |
| Eli Lilly and Company LLY | 2 | P1 2 | 1 | 0 |
| Genentech, Inc. | 2 | P4 1, P1 1 | 1 | 0 |
| icometrix | 2 | NA 2 | 0 | 1 |
| Jazz Pharmaceuticals JAZZ | 2 | P4 1, NA 1 | 0 | 1 |
| Kyverna Therapeutics KYTX | 2 | NA 1, P2 1 | 0 | 1 |
| Otto Bock Healthcare Products GmbH | 2 | NA 2 | 1 | 0 |
New-entrant sponsors: Oculis, AbelZeta Inc..
Recently stopped trials
- NCT06220669 Eli Lilly and Company - terminated: The interim analysis data failed to demonstrate the intended treatment effect. A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
- NCT04288011 BeCare Link LLC - terminated: Study was ended because of COVID19. Patients did not want to come to hospital for continued participation Validation of the BeCare Multiple Sclerosis Assessment App
- NCT03368664 Genzyme, a Sanofi Company - terminated: Enrolment formally closed earlier than planned due to recruitment challenges. A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activ
- NCT05949580 Hoffmann-La Roche - suspended: Transition of study Sponsor. Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple
- NCT07006805 Cabaletta Bio - withdrawn: The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the devel RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
- NCT04815967 Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC - terminated: Company/sponsor business decision; not due to or related to any safety concerns Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01 est. | P2 | Hope Biosciences Research Foundation | NCT06800404 "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" | Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosis | active not recruiting | 10 |
| 2027-01-21 est. | P3 | TG Therapeutics, Inc. TGTX | NCT05877963 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Relapsing Multiple Sclerosis | recruiting | 800 |
| 2027-02 est. | P3 | Celltrion | NCT05906992 A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | recruiting | 512 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-03 | P3 | Sandoz | NCT06847724 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | active not recruiting | 183 |
| 2026-11 est. | P3 | Immunic AG IMUX | NCT05201638 Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | active not recruiting | 1100 |
| 2026-11 est. | P3 | Immunic AG IMUX | NCT05134441 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | active not recruiting | 1121 |
| 2026-10-31 est. | P3 | TG Therapeutics, Inc. TGTX | NCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing | Relapsing Multiple Sclerosis | active not recruiting | 360 |
| 2026-10-30 est. | P1/P2 | Vidya Therapeutics Inc | NCT07085507 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients | Multiple Sclerosis | recruiting | 100 |
| 2026-10-22 est. | P3 | Hoffmann-La Roche | NCT03523858 A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | Progressive Multiple Sclerosis (PMS) | active not recruiting | 927 |
| 2026-09-17 | P2 | Hoffmann-La Roche | NCT07074886 A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | Multiple Sclerosis | active not recruiting | 193 |
| 2026-09-17 | P2 | Tiziana Life Sciences LTD TLSA | NCT06292923 A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | Secondary Progressive Multiple Sclerosis | completed | 54 |
| 2026-07-22 | P3 | Novartis Pharmaceuticals NVS | NCT05156281 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | active not recruiting | 1007 |
| 2026-07-21 | P3 | Novartis Pharmaceuticals NVS | NCT05147220 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) | Relapsing Multiple Sclerosis | active not recruiting | 1000 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "multiple sclerosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.